MD960288A - Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare - Google Patents

Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare

Info

Publication number
MD960288A
MD960288A MD96-0288A MD960288A MD960288A MD 960288 A MD960288 A MD 960288A MD 960288 A MD960288 A MD 960288A MD 960288 A MD960288 A MD 960288A
Authority
MD
Moldova
Prior art keywords
dnase
separating
forms
pharmaceutical composition
human
Prior art date
Application number
MD96-0288A
Other languages
English (en)
Russian (ru)
Inventor
John Frenz
Steven J. Shire
Mary B. Sliwkowski
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of MD960288A publication Critical patent/MD960288A/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Prezenta invenţie se referă la identificarea şi caracterizarea a două componente ale preparatului DNazei recombinante. Aceste componente reprezintă DNaza umană purificată dezaminată şi DNaza umană purificată nedezaminată. În prezenta invenţie sunt studiate metodele de separare a acestor componente şi utilizarea în scopuri farmaceutice a formei nedezaminate, în special în componenţa compoziţiilor, atunci când formele sunt situate în fiole de masă plastică, pentru administrare pacienţilor care suferă de dereglări cu caracter pulmonar.
MD96-0288A 1992-06-08 1993-05-28 Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare MD960288A (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/895,300 US5279823A (en) 1992-06-08 1992-06-08 Purified forms of DNASE
PCT/US1993/005136 WO1993025670A1 (en) 1992-06-08 1993-05-28 Purified forms of dnase

Publications (1)

Publication Number Publication Date
MD960288A true MD960288A (ro) 1998-01-31

Family

ID=25404292

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0288A MD960288A (ro) 1992-06-08 1993-05-28 Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare

Country Status (30)

Country Link
US (4) US5279823A (ro)
EP (2) EP0644932B1 (ro)
JP (1) JP3383307B2 (ro)
KR (2) KR100302092B1 (ro)
AT (2) ATE455557T1 (ro)
AU (1) AU682822B2 (ro)
BG (1) BG62335B1 (ro)
BR (1) BR9306670A (ro)
CA (1) CA2137237C (ro)
CZ (1) CZ293105B6 (ro)
DE (3) DE69329200T2 (ro)
DK (1) DK0644932T3 (ro)
ES (1) ES2150447T3 (ro)
FI (1) FI945549A0 (ro)
GB (1) GB2282140B (ro)
GE (1) GEP20002300B (ro)
GR (1) GR3034718T3 (ro)
HU (1) HU219549B (ro)
IL (1) IL105724A (ro)
MD (1) MD960288A (ro)
NO (1) NO318644B1 (ro)
NZ (1) NZ253559A (ro)
PL (1) PL175873B1 (ro)
PT (1) PT644932E (ro)
RO (1) RO117188B1 (ro)
RU (1) RU2238320C2 (ro)
SK (1) SK282957B6 (ro)
TJ (1) TJ396B (ro)
UA (1) UA46693C2 (ro)
WO (1) WO1993025670A1 (ro)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20010375A (ro) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Malaxor
MD2260C2 (ro) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Malaxor

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449968B1 (en) * 1988-12-23 1999-02-24 Genentech, Inc. Process for the preparation of human dnase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
JP3009224B2 (ja) 1994-03-04 2000-02-14 ジェネンテック インコーポレイテッド 改良されたｄｎアーゼ液体溶液
ATE268605T1 (de) * 1994-03-04 2004-06-15 Genentech Inc Pharmazeutische akzeptabel dnase zusammensetzung
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
EP0817839A1 (en) * 1994-05-05 1998-01-14 Human Genome Sciences, Inc. Human dnase
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
US5821103A (en) * 1994-09-06 1998-10-13 Tanuma; Sei-Ichi Deoxyribonuclease
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
NZ331063A (en) * 1996-02-05 2000-03-27 Inc Genentech Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
NZ507557A (en) † 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
AU2001235009B2 (en) * 2000-02-11 2004-10-07 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
HUE033623T2 (en) 2002-09-11 2017-12-28 Genentech Inc protein purification
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
WO2006084111A2 (en) * 2005-02-04 2006-08-10 Glaxo Group Limited Optimization of heterologous polypeptide expression
KR100655438B1 (ko) * 2005-08-25 2006-12-08 삼성전자주식회사 자기 기억 소자 및 그 형성 방법
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
EP2416156B1 (en) * 2006-10-18 2015-12-30 Periness Ltd. Method for determining a male fertility status
ES2533266T5 (es) 2007-10-30 2018-04-18 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
WO2009123950A2 (en) * 2008-03-31 2009-10-08 The Trustees Of The University Of Pennsylvania Chimera comprising bacterial cytotoxin and methods of using the same
EP3318635A1 (en) 2011-04-21 2018-05-09 University of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
RU2017101727A (ru) * 2014-06-25 2018-07-25 ДжейЭйчЭл БИОТЕК, ИНК. Способы и реагенты для очистки белков
JP6071018B2 (ja) 2014-10-31 2017-02-01 Ｊｃｒファーマ株式会社 組換えヒトＤＮａｓｅＩの製造方法
WO2017019876A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
US20230226138A1 (en) 2020-06-01 2023-07-20 Black Cat Bio Limited Compositions and methods for treating infections and netopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Canada Packers Limited Isolation and purification of deoxyribonuclease
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
EP0449968B1 (en) * 1988-12-23 1999-02-24 Genentech, Inc. Process for the preparation of human dnase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20010375A (ro) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Malaxor
MD2260C2 (ro) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Malaxor

Also Published As

Publication number Publication date
NZ253559A (en) 1996-11-26
IL105724A (en) 1997-06-10
US6932965B2 (en) 2005-08-23
GB2282140B (en) 1996-04-17
EP1013284B1 (en) 2010-01-20
JP3383307B2 (ja) 2003-03-04
CA2137237C (en) 2004-10-26
FI945549A7 (fi) 1994-11-25
HUT70468A (en) 1995-10-30
ES2150447T3 (es) 2000-12-01
DE4392749T1 (de) 1995-07-20
EP0644932B1 (en) 2000-08-09
SK149594A3 (en) 1996-01-10
US20030077267A1 (en) 2003-04-24
PL175873B1 (pl) 1999-02-26
KR100302092B1 (ko) 2001-10-22
US5279823A (en) 1994-01-18
DE69329200D1 (de) 2000-09-14
SK282957B6 (sk) 2003-01-09
JPH07507455A (ja) 1995-08-24
CZ303294A3 (en) 1995-06-14
ATE455557T1 (de) 2010-02-15
KR100323357B1 (ko) 2002-02-19
AU4398193A (en) 1994-01-04
HU219549B (hu) 2001-05-28
EP1013284A3 (en) 2000-08-30
BG62335B1 (bg) 1999-08-31
UA46693C2 (uk) 2002-06-17
GB2282140A (en) 1995-03-29
PT644932E (pt) 2001-02-28
HU9403512D0 (en) 1995-02-28
DE69334317D1 (de) 2010-03-11
FI945549L (fi) 1994-11-25
NO318644B1 (no) 2005-04-25
BG99234A (bg) 1995-07-28
CZ293105B6 (cs) 2004-02-18
CA2137237A1 (en) 1993-12-23
FI945549A0 (fi) 1994-11-25
AU682822B2 (en) 1997-10-23
ATE195340T1 (de) 2000-08-15
NO944752L (no) 1994-12-08
WO1993025670A1 (en) 1993-12-23
RU94046424A (ru) 1997-03-10
US6440412B1 (en) 2002-08-27
DK0644932T3 (da) 2001-01-02
EP1013284A2 (en) 2000-06-28
RO117188B1 (ro) 2001-11-30
US5783433A (en) 1998-07-21
NO944752D0 (no) 1994-12-08
EP0644932A1 (en) 1995-03-29
RU2238320C2 (ru) 2004-10-20
GB9423695D0 (en) 1995-01-11
TJ396B (en) 2004-12-29
DE69329200T2 (de) 2001-04-26
BR9306670A (pt) 1998-12-08
GR3034718T3 (en) 2001-01-31
IL105724A0 (en) 1993-09-22
GEP20002300B (en) 2000-11-25

Similar Documents

Publication Publication Date Title
MD960288A (ro) Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
CA2155933A1 (en) Pulmonary Administration of sCR1 and Other Complement Inhibitory Proteins
NO911854D0 (no) Fremgangsmaate for fremstilling av peptid-derivater.
BG101118A (en) Therapeutical compounds
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
ATE167057T1 (de) Sublinguales oder bukkales arzneimittel
AU1581692A (en) Inhibitors of human neutrophil elastase and human cathepsin g
LV11666A (lv) Farmaceitiskie preparati un medikamenti endotelialo traucejumu noversanai un arstesanai
AU4727889A (en) A novel purified thrombomodulin-like glycoprotein obtained from urine.
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
BG105342A (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
NO990450L (no) Behandling av sinnslidelser
MX9805065A (es) Nuevos derivados bi-aromaticos del dibenzofurano y su utilizacion en medicina humana o veterinaria asi como en cosmetica.
WO1999020291A3 (en) Pharmaceutical grade ginkgo biloba
EP0821969A3 (en) Medicinal Composition comprising TCF-II
DE69005160D1 (de) Verwendung von 5'-Deoxy-5'-methylthioadenosin, s-Adenylmethionin und deren Salzen zur Herstellung pharmazeutischer Präparate zur Förderung des Haarwuchses bei Patienten mit Kahlköpfigkeit.
EP0687687A3 (de) Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
WO1999021005A3 (en) Pharmaceutical grade st. john's wort
HUP9900401A3 (en) Novel substituted n-methyl-n-(4-(4-(1h-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases, pharmaceutical compositions containing them and their use
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
ATE181239T1 (de) Verwendung von biertreberextrakt zur herstellung von oral zu verabreichenden zubereitungen

Legal Events

Date Code Title Description
PD99 Pending application